Sirolimus as Primary Therapy for the Treatment of Chronic Graft Versus Host Disease
Trial ID or NCT#
Evaluate the clinical activity of sirolimus in combination with cyclosporine and corticosteroids as first line therapy for the treatment of chronic Graft Versus Host Disease.
An Open Label Study of Sirolimus as Primary Therapy for the Treatment of Chronic GVHD Following Allogeneic Bone Marrow Transplant
- - active chronic GvHD - ANC > 1000/mm^3 - therapeutic cyclosporine
- - uncontrolled systemic infection - elevated serum creatinine
Contact us to find out if this trial is right for you.